|Articles|July 1, 2009

How to Choose a Central IRB

Many Capabilities Need to Be Evaluated by the Sponsor or CRO When it Chooses a Central IRB

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

© putilov_denis - © putilov_denis - stock.adobe.com

FDA Approves Caplyta as Adjunctive Therapy for Major Depressive Disorder Based on Positive Phase III Results

ByAndy Studna, Senior Editor

November 7th 2025

ACT Brief: Designing Feasible Protocols and Breakthroughs in Obesity and Metabolic Research

ByAndy Studna, Senior Editor

November 7th 2025

Using AI and Tokenized Data to Match Patients to Protocols

ByMatt Holms,Andy Studna, Senior Editor

November 7th 2025

© Africa Studio - © Africa Studio - stock.adobe.com

Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg

ByAndy Studna, Senior Editor

November 6th 2025

Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity

ByAndy Studna, Senior Editor

November 6th 2025

How to Choose a Central IRB

Newsletter

Related Content

FDA Approves Caplyta as Adjunctive Therapy for Major Depressive Disorder Based on Positive Phase III Results

ACT Brief: Designing Feasible Protocols and Breakthroughs in Obesity and Metabolic Research

Using AI and Tokenized Data to Match Patients to Protocols

Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg

Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity

Trending on Applied Clinical Trials Online

FDA Approves Caplyta as Adjunctive Therapy for Major Depressive Disorder Based on Positive Phase III Results

Using AI and Tokenized Data to Match Patients to Protocols

ACT Brief: Designing Feasible Protocols and Breakthroughs in Obesity and Metabolic Research